Halozyme Therapeutics, Inc.

NasdaqGS:HALO Stock Report

Market Cap: US$5.7b

Halozyme Therapeutics Future Growth

Future criteria checks 5/6

Halozyme Therapeutics is forecast to grow earnings and revenue by 21.1% and 15.4% per annum respectively. EPS is expected to grow by 22.5% per annum. Return on equity is forecast to be 93% in 3 years.

Key information

21.1%

Earnings growth rate

22.5%

EPS growth rate

Biotechs earnings growth28.3%
Revenue growth rate15.4%
Future return on equity93.0%
Analyst coverage

Good

Last updated20 Nov 2024

Recent future growth updates

Recent updates

Halozyme: Fabless Or Not, The Stock Is Now A Steal On Evotec Deal

Nov 20

Halozyme: Looking For More Growth Following Record Q3 Earnings

Nov 05

Not Many Are Piling Into Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Yet

Oct 29
Not Many Are Piling Into Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Yet

Halozyme Therapeutics: Behind The Pullback

Oct 22

Halozyme Therapeutics, Inc.: Significantly Undervalued Growth Based On Current Fundamentals

Aug 14

Halozyme Therapeutics (NASDAQ:HALO) Has A Rock Solid Balance Sheet

Aug 13
Halozyme Therapeutics (NASDAQ:HALO) Has A Rock Solid Balance Sheet

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Not Flying Under The Radar

Jul 17
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Not Flying Under The Radar

Halozyme Therapeutics: The Story Brightens

Jun 07

Is Halozyme Therapeutics (NASDAQ:HALO) Using Too Much Debt?

Apr 26
Is Halozyme Therapeutics (NASDAQ:HALO) Using Too Much Debt?

Halozyme's Strategic Partnerships Fueling Next-Gen Therapeutics

Apr 10

Does Halozyme Therapeutics (NASDAQ:HALO) Deserve A Spot On Your Watchlist?

Apr 05
Does Halozyme Therapeutics (NASDAQ:HALO) Deserve A Spot On Your Watchlist?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Doing What It Can To Lift Shares

Mar 15
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Doing What It Can To Lift Shares

Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Feb 23
Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Halozyme Therapeutics: A Reasonable Value In An Overvalued Market

Jan 26

These 4 Measures Indicate That Halozyme Therapeutics (NASDAQ:HALO) Is Using Debt Safely

Jan 10
These 4 Measures Indicate That Halozyme Therapeutics (NASDAQ:HALO) Is Using Debt Safely

Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) Intrinsic Value Is Potentially 97% Above Its Share Price

Dec 14
Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) Intrinsic Value Is Potentially 97% Above Its Share Price

Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?

Sep 22
Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Could Be 50% Below Their Intrinsic Value Estimate

Jul 04
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Could Be 50% Below Their Intrinsic Value Estimate

We Think Halozyme Therapeutics (NASDAQ:HALO) Can Stay On Top Of Its Debt

May 09
We Think Halozyme Therapeutics (NASDAQ:HALO) Can Stay On Top Of Its Debt

Are Investors Undervaluing Halozyme Therapeutics, Inc. (NASDAQ:HALO) By 38%?

Mar 28
Are Investors Undervaluing Halozyme Therapeutics, Inc. (NASDAQ:HALO) By 38%?

Earnings and Revenue Growth Forecasts

NasdaqGS:HALO - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20261,393689N/AN/A6
12/31/20251,1525355725369
12/31/20241,00143947848710
9/30/2024947392393403N/A
6/30/2024873337408420N/A
3/31/2024863319424431N/A
12/31/2023829282373389N/A
9/30/2023781254354369N/A
6/30/2023774234293306N/A
3/31/2023705182264279N/A
12/31/2022660202235240N/A
9/30/2022581211238240N/A
6/30/2022487366290292N/A
3/31/2022472435287289N/A
12/31/2021443403298299N/A
9/30/2021463409265268N/A
6/30/2021412229150152N/A
3/31/2021331163116119N/A
12/31/20202681295355N/A
9/30/202020022-24-22N/A
6/30/2020180-40-60-58N/A
3/31/2020164-80-89-86N/A
12/31/2019196-72-89-85N/A
9/30/2019203-40-55-48N/A
6/30/2019182-43-43-38N/A
3/31/2019178-51-36-32N/A
12/31/2018152-80-54-49N/A
9/30/2018281469193N/A
6/30/201831976N/A132N/A
3/31/201831868N/A134N/A
12/31/201731763N/A134N/A
9/30/2017166-88N/A-35N/A
6/30/2017134-120N/A-64N/A
3/31/2017134-116N/A-60N/A
12/31/2016147-103N/A-50N/A
9/30/2016160-71N/A-50N/A
6/30/2016149-67N/A-58N/A
3/31/2016159-37N/A-36N/A
12/31/2015135-32N/A-37N/A
9/30/2015113-42N/A-23N/A
6/30/2015107-38N/A-19N/A
3/31/201582-57N/A-44N/A
12/31/201475-68N/A-48N/A
9/30/201457-85N/A-62N/A
6/30/201459-84N/A-61N/A
3/31/201455-91N/A-56N/A
12/31/201355-83N/A-49N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: HALO's forecast earnings growth (21.1% per year) is above the savings rate (2.6%).

Earnings vs Market: HALO's earnings (21.1% per year) are forecast to grow faster than the US market (15.3% per year).

High Growth Earnings: HALO's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: HALO's revenue (15.4% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: HALO's revenue (15.4% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: HALO's Return on Equity is forecast to be very high in 3 years time (93%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y